These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27239921)

  • 1. [Relationship between matrix metalloproteinase-3 levels and articular destructive changes in early and extended rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Karateev DE; Panasyuk EY; Smirnov AV; Cherkasova MV; Nasonov EL
    Ter Arkh; 2016; 88(5):13-18. PubMed ID: 27239921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.
    Young-Min S; Cawston T; Marshall N; Coady D; Christgau S; Saxne T; Robins S; Griffiths I
    Arthritis Rheum; 2007 Oct; 56(10):3236-47. PubMed ID: 17907159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.
    Connolly M; Mullan RH; McCormick J; Matthews C; Sullivan O; Kennedy A; FitzGerald O; Poole AR; Bresnihan B; Veale DJ; Fearon U
    Arthritis Rheum; 2012 Apr; 64(4):1035-45. PubMed ID: 22076945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs.
    Mamehara A; Sugimoto T; Sugiyama D; Morinobu S; Tsuji G; Kawano S; Morinobu A; Kumagai S
    Kobe J Med Sci; 2010 Sep; 56(3):E98-107. PubMed ID: 21063156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
    Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
    Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of tumor necrosis factor-α (G-308A) genetic variant with matrix metalloproteinase-9 activity and joint destruction in early rheumatoid arthritis.
    Stojanovic S; Bojana Stamenkovic ; Stoimenov TJ; Nedovic J; Zivkovic V; Despotovic M; Pavlovic D
    Clin Rheumatol; 2017 Jul; 36(7):1479-1485. PubMed ID: 28573370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
    Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
    Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study.
    Ma JD; Wei XN; Zheng DH; Mo YQ; Chen LF; Zhang X; Li JH; Dai L
    Arthritis Res Ther; 2015 Oct; 17():289. PubMed ID: 26467222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we prevent rapid radiological progression in patients with early rheumatoid arthritis?
    Heimans L; Wevers-deBoer KV; Ronday HK; Collée G; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
    Clin Rheumatol; 2015 Jan; 34(1):163-6. PubMed ID: 25431327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Misclassification of disease activity when assessing individual patients with early rheumatoid arthritis using disease activity indices that do not include joints of feet.
    Bakker MF; Jacobs JW; Kruize AA; van der Veen MJ; van Booma-Frankfort C; Vreugdenhil SA; Bijlsma JW; Lafeber FP; Welsing PM
    Ann Rheum Dis; 2012 Jun; 71(6):830-5. PubMed ID: 22128075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint.
    Meeuwisse CM; van der Linden MP; Rullmann TA; Allaart CF; Nelissen R; Huizinga TW; Garritsen A; Toes RE; van Schaik R; van der Helm-van Mil AH
    Arthritis Rheum; 2011 May; 63(5):1265-73. PubMed ID: 21305530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis.
    Zhou L; Wang G; Liu X; Song J; Chen L; Xu H
    Arthritis Res Ther; 2017 Nov; 19(1):250. PubMed ID: 29141665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study.
    Kubo S; Saito K; Hirata S; Fukuyo S; Yamaoka K; Sawamukai N; Nawata M; Iwata S; Mizuno Y; Tanaka Y
    Mod Rheumatol; 2014 Jan; 24(1):42-51. PubMed ID: 24261758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.
    Cunnane G; Fitzgerald O; Beeton C; Cawston TE; Bresnihan B
    Arthritis Rheum; 2001 Oct; 44(10):2263-74. PubMed ID: 11665967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
    Nishimoto N; Hashimoto J; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Murata N; van der Heijde D; Kishimoto T
    Ann Rheum Dis; 2007 Sep; 66(9):1162-7. PubMed ID: 17485422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [18F]fluorodeoxyglucose uptake as a predictor of large joint destruction in patients with rheumatoid arthritis.
    Yonemoto Y; Okamura K; Takeuchi K; Kaneko T; Kobayashi T; Okura C; Tsushima Y; Takagishi K
    Rheumatol Int; 2016 Jan; 36(1):109-15. PubMed ID: 26232929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up.
    Houseman M; Potter C; Marshall N; Lakey R; Cawston T; Griffiths I; Young-Min S; Isaacs JD
    Arthritis Res Ther; 2012 Feb; 14(1):R30. PubMed ID: 22314025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
    Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
    Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.